2024-2025 Global AI Trends Guide
Kayvon J. Paul
Associate Corporate & Finance
Kayvon’s corporate practice involves advising life sciences companies on a broad range of M&A and securities matters, including 33' and 34' Act reporting, Nasdaq and NYSE-related matters, capital market offerings (e.g., ATMs, CMPOs, RDOs, PIPEs), reverse stock splits, and general corporate governance. Kayvon has experience in reviewing and preparing SEC filings (e.g., Form 10-Q, Form 10-K, Form 8-K, Proxy Statements, Registration Statements), board and committee resolutions, corporate governance presentations and press releases. Kayvon also regularly advises senior executives and boards of directors, on securities, governance, transactional, and a range of other complex issues.
Kayvon’s pro bono practice involves preparing business formation documents, commercial agreements, and corporate policies for underrepresented entrepreneurs. Kayvon also works with the Homeless Advocacy Project to help housing insecure individuals apply for social security disability benefits.
During law school, Kayvon completed the U.S. Securities and Exchange Commission's honors program where he investigated insider trading schemes involving clinical-stage drug companies, and Ponzi schemes involving digital assets and real estate. Kayvon served as an extern for the Honorable Michael A. Shipp (D.N.J.) where he helped draft a securities opinion on a matter of first impression. Before finishing law school, Kayvon published two law review articles, including an article on digital market manipulation.
Prior to law school, Kayvon was a lobbyist for a reputable New Jersey government affairs firm, where he represented clients in healthcare, renewable energy, and cannabis industries on regulatory and legislative issues before the Governor’s Office and the New Jersey State Legislature.
Enstar Group Ltd (NASDAQ: ESGR) on its US$5.1bn acquisition by Sixth Street.
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) on its US$525m acquisition of Ironshore Therapeutics Inc.
Perspective Therapeutics, Inc. (NYSE: CATX) on its US$250m at-the-market equity offering program.
Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) on its US$230m follow-on public offering of equity securities.
Perspective Therapeutics, Inc. (NYSE: CATX) on its US$200m at-the-market equity offering program.
Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) on its US$161m follow-on public offering of equity securities.
Perspective Therapeutics, Inc. (NYSE: CATX) on its US$87.4m private placement shares of common stock.
Perspective Therapeutics, Inc. (NYSE: CATX) on its US$80m underwritten offering of equity securities.
Perspective Therapeutics, Inc. (NYSE: CATX) on its US$69m follow-on public offering of equity securities.
Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) on its US$50m at-the-market equity offering program.
Perspective Therapeutics, Inc. (NYSE: CATX) on its US$20.8m private placement financing.
Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) on the registration of shares under its long-term incentive plan, employee stock purchase plan and inducement nonqualified stock option awards.
Perspective Therapeutics, Inc. (NYSE: CATX) on the registration of shares under its equity incentive plan.
Phio Pharmaceuticals Corp (NASDAQ: PHIO) on its warrant inducement transaction.